title: Effect of terazosin on blood pressure and serum lipids.
abstract: In an open multicenter prospective study, the effects of short-term (4 weeks, n = 101) and long-term (6 months, n = 38) terazosin treatment on blood pressure, serum lipids and safety in the patients with mild to moderate essential hypertension were observed. Mean systolic and diastolic blood pressure in sitting position were significantly reduced by 16.4% and 14.0% respectively (P < 0.01) after 4 weeks of terazosin therapy, with the total efficacy rate being 87.1%. During a 6 month therapy, antihypertensive effect of terazosin could be maintained. Total cholesterol (TC) and low density lipoprotein (LDL) cholesterol in serum were significantly decreased P < 0.05-0.01) in patients with hypercholesterolemia (TC > or = 6 mmol/ml) after 4 week terazosin treatment; the levels of TC, LDL and triglyceride were significantly improved in hypertensive patients after 3-6 month terazosin treatment. The improvement of lipid metabolism was related to the dosage of terazosin but not to antihypertensive effects of terazosin. The results suggested that terazosin is effective in decreasing blood pressure and improving lipid metabolism. It may serve as a good antihypertensive agent for hypertensive patients with hypercholesterolemia.
authors.affiliation: Department of Clinical Pharmacology, School of Basic Medical Sciences, Tongji Medical University, Wuhan 430030.
authors.forename: P
authors.initials: P
authors.lastname: Gong
authors.forename: J
authors.initials: J
authors.lastname: Tang
authors.forename: L
authors.initials: L
authors.lastname: Cheng
authors.forename: Z
authors.initials: Z
authors.lastname: Lu
authors.forename: J
authors.initials: J
authors.lastname: Zhang
authors.forename: F
authors.initials: F
authors.lastname: Zeng
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure; D000075222:Essential Hypertension; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D050356:Lipid Metabolism; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011446:Prospective Studies
chemical_list: D000959:Antihypertensive Agents; C041226:Terazosin; D011224:Prazosin